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Aims: Guidelines recommend blood pressure (BP) in hypertensive patients should be 140 
systolic BP (SBP) and 90 diastolic BP (DBP) mmHg. This analysis assessed goal rate 
achievement in hypertensive patients receiving olmesartan-based treatment in the OLMEBEST 
study.
Methods: Patients with essential hypertension (DBP  90 mmHg and 110 mmHg) 
received open-label olmesartan medoxomil 20 mg/day (n = 2306). After 8 weeks, patients 
with DBP  90 mmHg (n = 627) were randomized to 4 weeks’ double-blind treatment with 
olmesartan 40 mg/day monotherapy or olmesartan 20 mg/day plus hydrochlorothiazide 
(HCTZ) 12.5 mg/day. For this analysis, the numbers and proportions of patients who achieved 
SBP  140 mmHg and/or DBP  90 mmHg at the end of the 4 weeks were calculated.
Results: In patients who achieved DBP normalization (90 mmHg) at week 8 (n = 1546) 
and continued open-label olmesartan 20 mg/day, 66.7% achieved SBP/DBP  140/90 mmHg 
at Week 12. In patients who did not achieve DBP normalization at Week 8, 26.8% of those 
randomized to olmesartan 40 mg/day and 42.5% of those randomized to olmesartan 20 mg/day 
plus HCTZ 12.5 mg/day achieved a SBP/DBP  140/90 mmHg at Week 12.
Conclusion: Olmesartan 40 mg/day and olmesartan 20 mg/day plus HCTZ 12.5 mg/day allow 
substantial proportions of patients to achieve BP goals.
Keywords: olmesartan medoxomil, hypertension, angiotensin II receptor blocker, goal rates, 
hydrochlorothiazide
Introduction
Hypertension is the leading cause of cardiovascular (CV) disease worldwide,1 and 
often occurs in conjunction with other risk factors such as dyslipidemia, diabetes 
and obesity, putting patients at substantial risk of CV events such as stroke and 
myocardial infarction.2 Due to the link between hypertension and CV risk, current 
guidelines recommend that all hypertensive patients should aim to reach the goal 
of 140 mmHg systolic blood pressure (SBP) and 90 mmHg diastolic BP (DBP).3,4 
For diabetic patients and those with an elevated CV risk due to associated conditions, 
the BP goal is 130/80 mmHg.
Current recommendations state that the initial therapeutic regimen used to achieve 
BP goal should be based on a low dose of either a single agent or dual combination 
therapy.3,4 However, the majority of patients with hypertension will not achieve 
BP goals with initial low-dose monotherapy, regardless of the antihypertensive agent 
that is used.4 Therefore in these patients, it is recommended to either increase the dose 
of single-agent therapy or initiate combination treatment.4Vascular Health and Risk Management 2009:5 724
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Blockade of the angiotensin II type 1 (AT1) receptor is 
an effective way to block the renin–angiotensin system and 
reduce BP.5 Olmesartan medoxomil, the most recently intro-
duced angiotensin receptor blocker (ARB), was launched in 
the US and Europe in 2002, and in comparative studies has 
been shown to provide greater BP control relative to other 
ARBs for the doses used.6–10 In patients who do not respond 
adequately to the standard 20 mg/day dose of olmesartan, 
the dose can be increased to 40 mg/day to increase efficacy 
without affecting tolerability.11,12
Combination therapy with olmesartan and hydrochloro-
thiazide (HCTZ) has been shown to provide BP-lowering 
efficacy that is greater than that achieved with either agent 
individually.13 OLMEBEST enrolled 2306 patients in a 
partially-randomized study in which olmesartan 40 mg/day 
and the combination of olmesartan 20 mg/day plus HCTZ 
12.5 mg/day provided additional well-tolerated BP reduc-
tions in patients who had not achieved DBP normalization 
(90 mmHg) after open-label treatment with olmesartan 
20 mg/day.14 The original report described the changes in 
BP seen during the OLMEBEST trial, and this additional 
analysis describes the levels of BP goal achievement obtained 
during this study.
Patients and methods
The design of the OLMEBEST study has been reported 
previously,14 so is described only briefly here.
study design
This was a prospective, parallel-group, double-blind, 
double-dummy study (Figure 1). The study population 
comprised males and females (aged 18 to 75 years) with 
essential hypertension (DBP  90 mmHg and 110 mmHg). 
After a placebo run in, the study comprised an 8-week 
open-label phase followed by a final 4-week phase in 
which patients continued with open-label therapy or 
underwent treatment intensification by random assignment 
to dose uptitration or combination therapy. Patients with 
a normalized DBP (90 mmHg) at the end of open-label 
treatment (Week 8) continued with this treatment for a 
further 4 weeks. Patients whose DBP was not normalized 
(ie, 90 mmHg) at Week 8 went on to receive 4 weeks 
of randomized therapy. Thus, the study comprised three 
consecutive phases:
1.  2 weeks of placebo treatment.
2.  8 weeks of open-label treatment with olmesartan 
20 mg/day.
3.  4 weeks of either:
  a.    randomized treatment in which patients with a DBP 
 90 mmHg at Week 8 received either olmesartan 
40 mg/day or olmesartan 20 mg/day plus HCTZ 
12.5 mg/day.
  b.    open-label treatment in which patients with a 
DBP  90 mmHg at Week 8 continued with olmes-
artan 20 mg/day.
Placebo  
Randomization
OLM 40 mg
OLM 20 mg + 
HCTZ 12.5 mg 
2 1 0 2 – 8
OLM 20 mg  
OLM 20 mg od
DBP < 90 mmHg
DBP ≥ 90 mmHg 
8
Open-label treatment
Baseline
Week
Randomized treatment
Figure 1 study design.
Abbreviations: DBP, diastolic blood pressure; OLM, olmesartan; HcTZ, hydrochlorothiazide.Vascular Health and Risk Management 2009:5 725
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Additional antihypertensive medications were not 
permitted during the study. The trial protocol was reviewed by 
an independent ethics committee or institutional review board 
in each country in which the trial was conducted. The trial 
was performed in accordance with the Declaration of Hel-
sinki, the ethical principles of the International Conference 
on Harmonisation Guidelines for Good Clinical Practice, and 
relevant national laws of participating countries. All patients 
provided written informed consent.
Assessments
The assessments and timing of assessments is described 
in full elsewhere and is described only briefly here.14
Patients attended a study center for six assessment visits 
between the initiation of screening and the completion of the 
partially randomized period; the timing of these visits was: 
Weeks –2, 0, 2, 4, 8, and 12, respectively. Physical investiga-
tions (including vital signs and resting electrocardiogram), 
blood sampling for laboratory examinations, and BP 
recordings were performed at Visit 1 (Week –2). At all visits, 
seated SBP and DBP were recorded for each patient in both 
arms, using an appropriately sized cuff and a well-calibrated 
sphygmomanometer with a maximum rate of descent of 
2 mmHg. Patients were questioned about possible adverse 
events (AEs) at Visit 2 (baseline) and all subsequent visits.
Since analysis of BP goal achievement was not included 
in the original study protocol, the aim of this additional 
analysis was to describe the level of BP control achieved 
at Visit 6 (Week 12) in patients who were randomized at 
Visit 5 (Week 8) to receive either olmesartan 40 mg/day or 
olmesartan 20 mg/day in combination with HCTZ 12.5 mg/day, 
as well as in the non-randomized patients who were still in 
the study at Week 8, and continued to receive olmesartan 
20 mg/day until Visit 6.
Patients
A total of 2173 patients completed the first 8 weeks of 
open-label treatment, of whom 71% (n = 1546) continued 
therapy with olmesartan 20 mg/day. A total of 627 patients 
did not achieve DBP normalization with olmesartan 
20 mg/day at Week 8 and were randomized to either olm-
esartan 40 mg/day (n = 302) or a combination of olmesar-
tan 20 mg/HCTZ 12.5 mg/day (n = 325). Demographic and 
clinical characteristics of these patients, approximately 10% 
of whom had diabetes mellitus, are shown in Table 1.
statistical analyses
Data were summarized by the calculation of absolute and 
relative frequencies of BP goal achievement. No inferential 
statistics were performed during this additional analysis. 
Missing values at Visit 6 (Week 12) were replaced on a last 
observation carried forwards basis.
Results
goal rate achievement
Overall, for the total population, the proportion of patients 
who achieved the combined BP goal of 140/90 mmHg 
at Week 12 was 57.6% (1251/2173). The proportions of 
the total population who achieved the individual goals 
Table 1 summary of demographic and clinical characteristics
Characteristic Non-randomized patients Randomized patients
  
 
Olmesartan  
20 mg/day  
(n = 1546)
Olmesartan  
40 mg/day 
(n = 302)
Olmesartan 20 mg/day + 
HCTZ 12.5 mg/day  
(n = 325)
Male, % 50.7 63.2 57.8
caucasian, % 98.7 97.4 98.5
Body mass index (kg/m2) 28.4 ± 4.8 29.4 ± 5.2 29.6 ± 5.2
Age (years) 55.1 ± 11.1 54.8 ± 10.9 54.9 ± 10.1
Diabetic, % 5.8 9.9 9.5
Baseline sBP (mmHg) 154.2 ± 13.0 160.8 ± 14.2 160.8 ± 14.0
Baseline DBP (mmHg)  96.6 ± 4.8 100.8 ± 5.6 100.2 ± 5.1
Data for the two randomized groups are reproduced from Barrios   V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to 
moderate essential hypertension: the OLMeBesT study. Clin Drug Investig. 2007;27:545–55814 with permission from Wolters Kluwer Health | Adis (© Adis Data information 
BV 2007.   All rights reserved). 
  Values are mean ± standard deviation, except where indicated.
Abbreviations: DBP, diastolic blood pressure; HcTZ, hydrochlorothiazide; sBP, systolic blood pressure.Vascular Health and Risk Management 2009:5 726
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of SBP  140 and DBP  90 mmHg were 62.7 and 
79.4%, respectively.
In patients who achieved DBP normalization (90 mmHg) 
at Week 8 and continued to receive open-label olmesartan 
20 mg/day until Week 12, approximately two thirds achieved 
the BP goal of 140/90 mmHg at Week 12 (Figure 2a). The 
proportions who achieved the individual goals of SBP  140 
and DBP  90 mmHg were 69.3% and 90.1%, respectively 
(Figure 2b). For patients whose DBP was 90 mmHg 
at Week 8, treatment intensification by randomization to 
either olmesartan 40 mg/day or olmesartan 20 mg/day 
plus HCTZ 12.5 mg/day resulted in improved BP control. 
By Week 12, the overall proportion of patients in the two 
randomized groups with DBP  90 mmHg was 53.1% 
(333/627), and the proportion who achieved the combined 
BP goal of 140/90 mmHg was 34.9% (219/627). Looking 
at the randomized treatment groups individually, the 
proportion of patients who achieved the combined BP goal 
of 140/90 mmHg was greater in the group that received olm-
esartan 20 mg/day plus HCTZ 12.5 mg/day (42.5% vs 26.8%; 
Figure 2a). Differences between these two groups in propor-
tions who achieved the individual goal of SBP  140 and 
DBP  90 mmHg were somewhat less marked (Figure 2b).
For patients who received olmesartan monotherapy 
only (ie, non-randomized patients who received olmesartan 
20 mg/day plus the randomized patients who received 
olmesartan 40 mg/day), the proportion who achieved the 
combined BP goal of 140/90 mmHg at Week 12 was 60.3% 
(1113/1848). The proportions of monotherapy recipients who 
achieved the individual goals of SBP  140 and DBP  
90 mmHg were 64.5% and 83.1%, respectively.
In addition to the combined BP goal of 140/90 mmHg, 
the proportion of  patients who achieved a more rigorous com-
bined BP goal of 130/85 mmHg was also assessed. For all 
patients (randomized plus non-randomized) the proportion 
who achieved this goal at Week 12 was 27.4% (596/2173). 
For the randomized groups, the overall proportion of patients 
who achieved the BP goal of 130/85 mmHg at Week 12 
was 10.4% (65/627). In the individual randomized groups, 
the proportion of patients who achieved the combined 
BP goal of 130/85 mmHg was higher in the group that 
received combination therapy (Figure 2a). In patients who 
received olmesartan monotherapy only, 29.9% (553/1848) 
achieved the 130/85 mmHg goal.
Looking at patients with diabetes among the non-
randomized patients, 16.4% achieved the guideline-
recommended goal of 130/80 mmHg at Week 12. For 
randomized patients, the proportion who achieved the 
130/80 mmHg goal was 6.7% and 9.7% in the olmesartan 
40 mg/day  and  olmesartan  20 mg/day  plus  HCTZ 
12.5 mg/day groups, respectively.
safety evaluation
AEs reported in the OLMEBEST study have been reported 
previously,14 and are described only briefly here. Generally, 
similar proportions of patients experienced AEs of mild, 
moderate and severe intensity during open-label treatment 
and in the two randomized treatment groups. During 
randomized treatment, olmesartan 40 mg/day was associ-
ated with a somewhat lower frequency of AEs than olmes-
artan 20 mg plus HCTZ 12.5 mg/day (21.5% vs 28.3% of 
patients, respectively). The majority (72.4%) of the AEs 
were classified as being of mild intensity and only 6.4% 
of events were considered probably or definitely related to 
study drug. Dizziness (1.4%) and headache (2.5%) were 
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Figure 2 Blood pressure (BP) goal achievement rates at   Week 12 for (a) combined 
systolic and diastolic BP (sBP and DBP) goals and for (b) individual sBP and DBP 
goals.Vascular Health and Risk Management 2009:5 727
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the most commonly reported AEs in each group during 
randomized treatment. AEs that led to withdrawal from 
the study were reported in 7 patients in the olmesartan 
40 mg group and 9 in the olmesartan plus HCTZ group. 
No serious AEs were considered to be related to study 
medication.
At week 12, patients treated with olmesartan 40 mg/day 
and olmesartan 20 mg plus HCTZ 12.5 mg/day showed 
comparable mean serum concentrations of glucose (5.55 and 
5.63 mmol/L, respectively), sodium (140.9 and 140.3 mmol/L, 
respectively), potassium (4.40 and 4.26 mmol/L, respectively), 
and creatinine (82.8 and 81.6 µmol/L, respectively). The 
incidence of laboratory measurements reported as being 
of potential clinical relevance during randomized treat-
ment was low. Increases in serum levels were reported 
for alanine aminotransferase (olmesartan 20 mg plus 
HCTZ 12.5 mg/day group, n = 2), aspartate aminotrans-
ferase (olmesartan 20 mg plus HCTZ 12.5 mg/day, n = 2), 
γ-glutamyltransferase (olmesartan 40 mg/day, n = 2; and 
olmesartan 20 mg plus HCTZ 12.5 mg/day, n = 4), glucose 
(olmesartan 40 mg/day, n = 1; and olmesartan 20 mg plus 
HCTZ 12.5 mg/day, n = 3), and creatinine (olmesartan 
40 mg/day, n = 1).
Discussion
OLMEBEST was a large study involving approximately 
2300 patients that confirmed the efficacy of the standard 
maintenance dose of olmesartan 20 mg/day and suggested 
that for patients who did not show a sufficient response, 
antihypertensive efficacy could be increased by either dose-
titration or the addition of a low dose of HCTZ. In each of 
the two randomized groups, additional reductions in SBP 
and DBP were seen relative to the end of the open-label 
monotherapy phase.14
Monotherapy dose-titration or combination therapy is 
recommended in patients who do not respond adequately 
to initial monotherapy.4 The results of this analysis show 
that treatment of hypertensive patients with olmesartan 
20 mg/day plus HCTZ 12.5 mg/day or uptitration to 
olmesartan 40 mg/day for patients with a sub-optimal 
response, enabled more than half of all patients to achieve 
an SBP/DBP target of 140/90 mmHg in OLMEBEST. 
Looking at the whole study population, the proportion of 
patients who achieved the 140/90 mmHg goal approached 
60% at Week 12.
Approximately 70% of patients achieved DBP normal-
ization (90 mmHg) after 8 weeks of open-label treatment 
with olmesartan 20 mg/day. However, approximately 30% 
of patients did not achieve DBP normalization and went on 
to receive randomized treatment. By the end of the study, 
more than half of these randomized patients who had already 
shown an inadequate DBP response to olmesartan 20 mg/day 
had achieved DBP normalisation, and more than a third had 
achieved the 140/90 mmHg goal.
The rate of DBP normalization achieved with olm-
esartan 20 mg/day during the 8-week open-label phase 
was higher than anticipated during the design of the 
study. Thus, fewer patients than planned were random-
ized to treatment, which meant that the study did not 
have sufficient power to detect non-inferiority between 
the two treatment groups. As such, it was not possible 
to determine whether there was a statistically significant 
difference between the two randomized groups. Despite 
this limitation, the olmesartan plus HCTZ arm appeared 
to be associated with a higher level of goal achievement 
compared with uptitration to olmesartan 40 mg/day. This 
finding is probably explained by the complementary modes 
of action of ARBs and HCTS that result in increased 
antihypertensive efficacy.15 Indeed, the combination of 
olmesartan and HCTZ has previously been associated 
with larger BP reductions compared with uptitration of 
component monotherapy.16
The partially-randomized design of the OLMEBEST 
study makes it difficult to compare the results with those 
of other studies. Adding HCTZ to an ARB increases 
antihypertensive efficacy, as outlined above, and the com-
bination of olmesartan with HCTZ has been available for 
several years.17 Rump et al looked at the effects of treat-
ment with olmesartan 20 mg/day plus HCTZ 12.5 mg/day 
and found that after 12 weeks the proportion of patients 
with BP  140/90 mmHg was 43%,18 which is in line 
with the results of the present analysis for the random-
ized group that received combination therapy. Combining 
HCTZ with other ARBs has also been shown to result in 
comparable levels of goal rate achievement. The com-
bination of HCTZ 12.5 mg/day with either candesartan 
8 mg/day or valsartan 80 mg/day resulted in approximately 
49% of hypertensive patients achieving 140/90 mmHg 
with each combination,19 although a more recent analysis 
by Weir et al indicates a level closer to 40% for valsartan 
plus HCTZ.20 For dose-titration, Neutel et al conducted a 
forced-titration study in which patients were treated with 
the aim of achieving a BP target of 130/85 mmHg.21 
During the initial monotherapy phase of the present study, 
patients received olmesartan 20 mg/day for 4 weeks, 
followed by uptitration to olmesartan 40 mg/day for the next Vascular Health and Risk Management 2009:5 728
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4 weeks for patients who did not achieve target BP. At the 
end of the 8-week monotherapy phase, the proportion of 
patients who achieved the BP target of 140/90 mmHg was 
58.7%, a value similar to that observed for all patients who 
received olmesartan as monotherapy (either 20 mg/day or 
40 mg/day) in OLMEBEST.
In many countries, overall levels of BP control in 
the general population are suboptimal22–24 and need to 
be improved in order to lower the rate of CV events 
such as stroke and myocardial infarction. Increasing the 
dose of monotherapy or using a two-drug combination 
is recommended in order to achieve BP control.4 The 
results of the present analysis support this approach, 
and suggest that each of these approaches can be used 
to increase the number of patients achieving the recom-
mended 140/90 mmHg hypertension threshold. More-
over, this analysis also looked at the more rigorous BP goal 
of 130/85 mmHg and found that by Week 12, 27.4% of 
all patients had achieved this goal and had thus achieved 
a level of BP control below the ESH-ESC threshold for 
high normal4 and so could be regarded as being within 
the normal range.
In conclusion, treatment with olmesartan 20 mg/day 
enabled a substantial proportion of patients to achieve 
the guideline-recommended goal of 140/90 mmHg, and 
approximately two-thirds of patients receiving olmesartan 
20 mg/day at the end of the study achieved this goal. For 
patients who had been unable to normalize their DBP with 
olmesartan 20 mg/day, addition of HCTZ 12.5 mg/day to 
the regimen, or dose uptitration to olmesartan 40 mg/day 
enabled even more patients to control their BP so that 
overall, nearly 60% of patients had a BP  140/90 mmHg 
by study end. Such findings indicate that both uptitra-
tion and combination with HCTZ are effective options 
to achieve increased BP reduction and goal attainment, 
but clinical recommendations as to the most appropriate 
regimen must be decided by physicians based on indi-
vidual patients’ needs.
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